| 21.57 -0.46 (-2.09%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 31.19  |
1-year : | 35.71 |
| Resists | First : | 26.71 |
Second : | 30.57 |
| Pivot price | 23.66 |
|||
| Supports | First : | 20.45 | Second : | 17.01 |
| MAs | MA(5) : | 21.46 |
MA(20) : | 24.9 |
| MA(100) : | 32.24 |
MA(250) : | 30.99 |
|
| MACD | MACD : | -2.8  |
Signal : | -2.7 |
| %K %D | K(14,3) : | 13.2 |
D(3) : | 8.2 |
| RSI | RSI(14): 26.3 |
|||
| 52-week | High : | 41.72 | Low : | 20.45 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ AZTA ] has closed above bottom band by 23.9%. Bollinger Bands are 10.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 22.57 - 22.68 | 22.68 - 22.77 |
| Low: | 21.12 - 21.27 | 21.27 - 21.39 |
| Close: | 21.36 - 21.59 | 21.59 - 21.77 |
Azenta, Inc. provides life science sample exploration and management solutions for the life sciences market in North America, Europe, China, the Asia Pacific, and internationally. The company operates through two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold sample management systems for compound and biological sample storage; equipment for sample preparation and handling; consumables; and instruments that help customers in managing samples throughout their research discovery and development workflows. The Life Sciences Services segment provides comprehensive sample management programs, integrated cold chain solutions, informatics, and sample-based laboratory services to advance scientific research and support drug development. This segment's services include sample storage, genomic sequencing, gene synthesis, laboratory processing, laboratory analysis, biospecimen procurement, and other support services. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Chelmsford, Massachusetts.
Tue, 17 Mar 2026
Azenta's (AZTA) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Tue, 17 Mar 2026
Needham Reiterates Buy Rating on Azenta (AZTA) with Price Target of $44 | AZTA Stock News - GuruFocus
Mon, 16 Mar 2026
Azenta (NASDAQ:AZTA) Hits New 1-Year Low - Here's What Happened - MarketBeat
Tue, 10 Mar 2026
Azenta, Inc. (AZTA) Uk Biocentre Limited - M&A Call - Slideshow (NASDAQ:AZTA) 2026-03-10 - Seeking Alpha
Wed, 04 Mar 2026
Azenta Completes Strategic Acquisition of UK Biocentre Limited, to Expand Biorepository Capabilities - PR Newswire
Mon, 02 Mar 2026
3 Reasons AZTA is Risky and 1 Stock to Buy Instead - Finviz
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 46 (M) |
| Shares Float | 41 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 115.5 (%) |
| Shares Short | 5,070 (K) |
| Shares Short P.Month | 4,060 (K) |
| EPS | 0.57 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 37.25 |
| Profit Margin | -10.2 % |
| Operating Margin | -4.1 % |
| Return on Assets (ttm) | -0.6 % |
| Return on Equity (ttm) | 1.5 % |
| Qtrly Rev. Growth | 0.8 % |
| Gross Profit (p.s.) | 5.75 |
| Sales Per Share | 12.91 |
| EBITDA (p.s.) | 0.81 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 63 (M) |
| Levered Free Cash Flow | 109 (M) |
| PE Ratio | 37.18 |
| PEG Ratio | 0 |
| Price to Book value | 0.57 |
| Price to Sales | 1.66 |
| Price to Cash Flow | 15.71 |
| Dividend | 0.1 |
| Forward Dividend | 0 |
| Dividend Yield | 0.4% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|